Business Description
Cidara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1717571079
Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.34 | |||||
| Equity-to-Asset | -0.12 | |||||
| Debt-to-Equity | -0.59 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -9.02 | |||||
| Beneish M-Score | -0.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36 | |||||
| 3-Year EBITDA Growth Rate | 45.3 | |||||
| 3-Year EPS without NRI Growth Rate | 47.5 | |||||
| 3-Year FCF Growth Rate | 41.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.34 | |||||
| 9-Day RSI | 22.78 | |||||
| 14-Day RSI | 31.04 | |||||
| 6-1 Month Momentum % | -10.05 | |||||
| 12-1 Month Momentum % | -25.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | |||||
| Quick Ratio | 0.81 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 840.24 | |||||
| Days Sales Outstanding | 64.25 | |||||
| Days Payable | 707.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.4 | |||||
| Shareholder Yield % | -46.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 97.62 | |||||
| Operating Margin % | -38.31 | |||||
| Net Margin % | -35.88 | |||||
| FCF Margin % | -35.79 | |||||
| ROE % | -414.8 | |||||
| ROA % | -34.99 | |||||
| ROIC % | -91.25 | |||||
| ROC (Joel Greenblatt) % | -718.78 | |||||
| ROCE % | -105.36 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.96 | |||||
| EV-to-EBIT | -1.17 | |||||
| EV-to-EBITDA | -1.19 | |||||
| EV-to-Revenue | 0.45 | |||||
| EV-to-Forward-Revenue | 0.69 | |||||
| EV-to-FCF | -1.25 | |||||
| Earnings Yield (Greenblatt) % | -85.47 | |||||
| FCF Yield % | -38.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cidara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 59.344 | ||
| EPS (TTM) (€) | -4.811 | ||
| Beta | 0 | ||
| Volatility % | 70.6 | ||
| 14-Day RSI | 31.04 | ||
| 14-Day ATR (€) | 1.203244 | ||
| 20-Day SMA (€) | 16.0701 | ||
| 12-1 Month Momentum % | -25.82 | ||
| 52-Week Range (€) | 9.464 - 26.64 | ||
| Shares Outstanding (Mil) | 4.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cidara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cidara Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cidara Therapeutics Inc Frequently Asked Questions
What is Cidara Therapeutics Inc(STU:20D0)'s stock price today?
The current price of STU:20D0 is €9.72. The 52 week high of STU:20D0 is €26.64 and 52 week low is €9.46.
When is next earnings date of Cidara Therapeutics Inc(STU:20D0)?
The next earnings date of Cidara Therapeutics Inc(STU:20D0) is 2024-05-10 Est..
Does Cidara Therapeutics Inc(STU:20D0) pay dividends? If so, how much?
Cidara Therapeutics Inc(STU:20D0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers